1. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan
- Author
-
Toru Kumagai, Osamu Kanai, Kyoichi Okishio, Keisuke Aoe, Isamu Okamoto, Kayoko Kibata, Makiko Yomota, Junichi Shimizu, Hiroshi Tanaka, Daichi Fujimoto, Hiroshi Sakai, Young Hak Kim, Keiko Mizuno, Jun-ya Ueda, Takashi Haku, Yuichiro Ohe, Takeshi Masuda, Satoshi Oizumi, Ryo Morita, Hiroaki Tsukamoto, Makoto Nishio, Haruhiro Saito, Toshiyuki Kozuki, Hirotoshi Hoshiyama, Hiroyuki Suzuki, and Osamu Hataji
- Subjects
Adult ,Male ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Adenocarcinoma of Lung ,Subgroup analysis ,Gene mutation ,03 medical and health sciences ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Japan ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Humans ,Lung cancer ,Survival rate ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Incidence (epidemiology) ,Retrospective cohort study ,Middle Aged ,Prognosis ,medicine.disease ,Survival Rate ,Clinical trial ,Nivolumab ,030104 developmental biology ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Female ,business ,Follow-Up Studies - Abstract
Objectives To describe the treatment patterns and determine the effectiveness and safety of nivolumab treatment for non-small cell lung cancer (NSCLC) in real-world setting in Japan. Materials and methods Japanese patients with NSCLC who received nivolumab were analyzed retrospectively. Patients who had started nivolumab treatment between April 2016 and December 2016 were enrolled. Information regarding patient demographics and clinical backgrounds, treatment patterns from diagnosis to post-nivolumab treatment, effectiveness and safety of nivolumab treatment and that of treatments just before and after nivolumab treatment, and programmed death-ligand 1 (PD-L1) expression status, if available, were collected. Factors associated with nivolumab effectiveness identified by univariate and multivariate analyses were further investigated for plotting Kaplan-Meier curves of epidermal growth factor receptor (EGFR) gene mutation status, PD-L1 expression status, and Eastern Cooperative Oncology Group performance status (ECOG PS). Results In this study, 901 NSCLC patients were enrolled. Nivolumab was used the most as a second line treatment with a median number of nivolumab doses of five. The median overall survival (OS) was 14.6 months, one-year survival rate was 54.3 %, and median progression-free survival (PFS) was 2.1 months. The objective response rate was 20.5 % and disease control rate was 57.4 %. According to multivariate analyses, better OS and PFS were associated with favorable ECOG PS and absence of liver metastasis. Better PFS was observed in patients without EGFR mutation and patients with smoking history. PFS and best overall response in PD-L1 expression subgroups were expression level-dependent. The overall incidence of irAEs was 45.8 %, and the incidence of adverse events of grade 3 or higher was 14.0 %. Conclusion The real-world effectiveness and safety of nivolumab is consistent with that reported by previous clinical trials and other real-world data. Subgroup analysis showed that ECOG PS, EGFR mutation status, smoking status, and PD-L1 were associated with the effectiveness of nivolumab.
- Published
- 2020
- Full Text
- View/download PDF